- Differences in immune responses to IL-6 inhibition therapy between male and female COVID-19 patients News-Medical.Net
- A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19 Science
- View Full coverage on Google News